Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 08, 2023 03:00 ET | Source: Antev

Antev Receives US FDA Guidance on Teverelix® Phase 3 Trial Design for Treating Advanced Prostate Cancer Patients with Increased Cardiovascular Risk

Phase 3 aims to demonstrate cardiovascular benefit of Teverelix versus GnRH agonists.Up to 30% of advanced prostate cancer patients on Androgen Deprivation Therapy have pre-existing Cardiovascular...